Mucolytics: complete pharmacology and clinical use
Mucolytics are mucoactive medicines that reduce sputum viscosity, alter mucus structure or digest components of tenacious airway secretions. By making sputum easier to mobilise, they can improve expectoration and airway clearance in selected diseases. The class includes bromhexine, ambroxol, N-acetylcysteine (acetylcysteine), carbocisteine, dornase alfa and inhaled hypertonic saline.
Learning objectives
- Explain mucus composition, mucociliary clearance and the rationale for mucolytic therapy.
- Classify mucolytics according to their chemical or enzymatic action.
- Describe each major drug’s mechanism, clinical indications, doses, contraindications, adverse effects, interactions and monitoring.
- Use mucolytics appropriately in COPD, cystic fibrosis, bronchiectasis, tracheostomy care and selected mucus-plug situations.
- Recognise when mucus retention is an airway emergency requiring suction, physiotherapy, bronchoscopy or ventilatory support.
Airway mucus and normal clearance
Airway mucus contains water, mucin glycoproteins, salts, lipids, cellular debris, DNA, actin and inflammatory proteins. A hydrated periciliary layer allows cilia to beat and move the mucus blanket toward the pharynx. Infection, dehydration, smoking, airway inflammation, neutrophil DNA, bacterial debris and epithelial injury can produce thick, sticky sputum. Ciliary dysfunction, weak cough, pain, neuromuscular disease and impaired consciousness then prevent clearance.
| Problem | Effect on mucus | Helpful clinical response |
|---|---|---|
| Dehydration or fever | Reduces water content and increases viscosity. | Assess volume status and provide appropriate fluids; do not assume a mucolytic alone will correct it. |
| Neutrophilic inflammation | Extracellular DNA and actin form a viscous mesh. | Dornase alfa may be useful in cystic fibrosis; treat infection/inflammation and provide airway-clearance therapy. |
| Disulfide-linked mucoproteins | Mucin polymers remain thick and tenacious. | Acetylcysteine can split disulfide bonds; watch for bronchospasm and excessive liquefied secretions. |
| Abnormal mucin production | Large volume of difficult-to-clear sputum. | Selected carbocisteine, bromhexine or ambroxol; review response and stop if ineffective. |
Classification of mucolytics
Thiol mucolytic
Acetylcysteine (NAC) supplies a free sulfhydryl group that disrupts disulfide bonds in mucoproteins. It is also a systemic antidote for paracetamol poisoning, but inhaled mucolytic and antidote regimens are not interchangeable.
Secretolytic/mucokinetic agents
Bromhexine and its active metabolite ambroxol alter mucopolysaccharide structure, improve secretion movement and may enhance surfactant and ciliary activity.
Mucoregulator
Carbocisteine helps normalise the composition and viscosity of mucus, particularly in chronic productive respiratory disease.
Enzyme mucolytic
Dornase alfa is recombinant human DNase. It cleaves extracellular DNA in purulent sputum, especially in cystic fibrosis.
Osmotic airway hydrator
Hypertonic saline draws water onto the airway surface and can assist sputum mobilisation in bronchiectasis or cystic fibrosis protocols.
1. Bromhexine
Bromhexine is a semi-synthetic derivative related to the vasicine alkaloid. It reduces sputum viscosity by altering mucopolysaccharide fibres, stimulating lysosomal activity and supporting mucociliary transport. It may increase the volume of less-viscous secretions, so the patient must be able to cough or receive airway-clearance support.
| Feature | Clinical detail |
|---|---|
| Indications | Respiratory disorders with excessive or abnormally viscous mucus, such as productive bronchitis and selected chronic obstructive airway disease, according to local licensing. |
| Common adult dose | 8 mg PO three times daily; some products allow 8–16 mg every 8 hours, with a maximum determined by the product. |
| Paediatric principle | Use age- and formulation-specific dosing only. Common product examples use 4 mg two to four times daily in school-age children; do not copy adult doses or use unlicensed preparations in young children. |
| Adverse effects | Nausea, vomiting, diarrhoea, abdominal discomfort, headache, dizziness and rash. Rare serious skin or mucosal reactions require immediate discontinuation and urgent assessment. |
| Contraindications/cautions | Hypersensitivity; caution with active peptic ulcer disease, severe hepatic/renal impairment and patients unable to clear increased secretions. |
2. Ambroxol
Ambroxol is an active metabolite of bromhexine. It has mucolytic and mucokinetic actions, may stimulate pulmonary surfactant, improve ciliary transport and reduce sputum adhesion. It is used in many countries as oral tablets, syrup or inhaled preparations; exact strengths vary substantially.
| Feature | Clinical detail |
|---|---|
| Common adult dose | A common immediate-release teaching regimen is 30 mg PO three times daily; product protocols may use 60–120 mg/day in two or three divided doses. |
| Children | Use licensed syrup and weight/age guidance. A common example is 15 mg two to three times daily in children 6–12 years, but local product concentration must be checked. |
| Adverse effects | Gastrointestinal upset, nausea, diarrhoea, dry mouth, altered taste, rash and hypersensitivity. Rare severe cutaneous adverse reactions have been reported. |
| Precautions | Caution in peptic ulcer disease, severe renal/hepatic dysfunction and patients with weak cough or an ineffective airway-clearance mechanism. |
3. Acetylcysteine (N-acetylcysteine, NAC)
Acetylcysteine directly breaks disulfide bonds between mucoprotein chains. This rapidly reduces mucus viscosity. The solution also has a strong smell and can provoke coughing, bronchospasm and a sudden increase in thin secretions. The patient needs a way to expectorate or be suctioned.
| Route/setting | Common dose information | Safety detail |
|---|---|---|
| Nebulised 20% solution | Common dose: 3–5 mL nebulised three or four times daily. Product information allows 1–10 mL every 2–6 h under clinical supervision. | Bronchodilator may be given first in patients prone to bronchospasm. Monitor wheeze, oxygenation, cough and secretion volume. |
| Nebulised 10% solution | Common dose: 6–10 mL nebulised three or four times daily; product range may be 2–20 mL every 2–6 h. | Check concentration carefully; 10% and 20% volumes are not interchangeable. |
| Direct airway instillation | 1–2 mL of 10–20% solution may be instilled as often as every hour in selected intubated/tracheostomy patients. | Only by trained clinicians with suction and airway monitoring; bronchorrhoea and airway obstruction can worsen if secretions are not removed. |
| Oral NAC for COPD | Many formularies use 600 mg once daily or 600 mg twice daily depending on product and disease pathway. | Follow local formulary; benefit is not automatic in acute viral cough. |
Acetylcysteine adverse effects and interactions
- Bronchospasm: more likely in asthma or hyperreactive airways. Stop treatment and give appropriate bronchodilator therapy if severe wheeze occurs.
- Bronchorrhoea: thin secretions can become too abundant for a weak or fatigued patient to clear.
- Gastrointestinal effects: nausea, vomiting and abdominal discomfort, especially with oral doses.
- Hypersensitivity: rash, angioedema, hypotension or anaphylactoid reaction requires immediate clinical treatment.
- Antibiotics: separate oral NAC from some antibiotics according to the product/local guidance; do not mix nebulised solutions with other medicines unless compatibility is confirmed.
- Nitroglycerin: acetylcysteine may enhance vasodilation and headache; monitor blood pressure where used together.
4. Carbocisteine
Carbocisteine (S-carboxymethylcysteine) is a mucoregulator. It is thought to help restore the balance between acidic and neutral mucin glycoproteins, reducing mucus viscosity and improving expectoration. It is an oral drug, often considered for COPD with chronic productive cough and difficulty clearing sputum.
| Feature | Common adult teaching information |
|---|---|
| Starting dose | 750 mg PO three times daily (2 × 375 mg capsules three times daily; approximately 2.25 g/day). |
| When improved | Reduce to about 500 mg three times daily or a product-equivalent maintenance dose, such as 1.5 g/day in divided doses. |
| Trial and review | Assess sputum volume, viscosity, exacerbations, breathlessness and ability to clear secretions. Stop if there is no meaningful benefit after a reasonable trial. |
| Contraindications/cautions | Active peptic ulcer disease, previous GI bleeding, pregnancy/breastfeeding review, and children below the licensed age for the formulation. |
| Adverse effects | Nausea, diarrhoea, abdominal pain, GI bleeding and hypersensitivity reactions. |
Evidence and guidelines are indication-specific. Mucolytic therapy may be considered in COPD with chronic productive cough, but it should not be offered routinely for an uncomplicated acute upper-respiratory infection or acute bronchitis. Optimise smoking cessation, inhaled therapy, vaccinations, pulmonary rehabilitation and airway-clearance skills first.
5. Dornase alfa
Dornase alfa is recombinant human deoxyribonuclease I. Neutrophils disintegrating in infected mucus release DNA, which forms a sticky web and greatly increases sputum viscosity. Dornase alfa cleaves this extracellular DNA. It is especially useful in cystic fibrosis and is not a general-purpose mucolytic for ordinary bronchitis or COPD.
| Feature | Clinical detail |
|---|---|
| Licensed use | Adjunct to standard therapy in patients with cystic fibrosis to improve pulmonary function. |
| Common dose | 2.5 mg (one single-dose ampoule) inhaled once daily using a recommended jet or vibrating-mesh nebuliser. |
| Selected severe disease | Specialist CF teams may prescribe twice-daily therapy in selected patients; never escalate independently. |
| Adverse effects | Voice alteration, pharyngitis, rash, chest pain, conjunctivitis, dyspnoea and transient pulmonary-function changes. |
| Administration cautions | Do not mix in the nebuliser with other medicines. Store and handle according to product instructions; use airway-clearance physiotherapy as directed. |
6. Hypertonic saline and airway hydration
Inhaled hypertonic saline, commonly 3% or 7%, increases airway-surface hydration by osmosis and may improve sputum expectoration. It is used in some cystic fibrosis and bronchiectasis programmes. Concentration, volume, frequency and pre-treatment differ by local protocol.
- Give the prescribed concentration through the correct nebuliser; do not improvise concentrated salt solutions.
- Bronchodilator pre-treatment is often considered in patients with bronchial hyperreactivity.
- Monitor for cough, chest tightness, wheeze, bronchospasm, desaturation and excessive sputum.
- Combine with chest physiotherapy, active-cycle breathing, positive expiratory-pressure devices or suction where indicated.
- Do not use hypertonic saline as a replacement for antibiotics in an infected exacerbation.
Comparison of major mucolytics
| Drug | Target | Typical setting | Main limitation |
|---|---|---|---|
| Bromhexine | Mucopolysaccharide structure and mucociliary transport | Productive bronchial disorders where locally licensed | Evidence and formulations vary; GI and hypersensitivity effects |
| Ambroxol | Bromhexine metabolite; mucokinetic and surfactant effects | Productive cough with abnormal mucus | Product variation and limited role in acute uncomplicated cough |
| Acetylcysteine | Disulfide bonds in mucoproteins | Thick secretions, selected COPD/bronchiectasis, airway toileting | Bronchospasm and bronchorrhoea; formulation confusion |
| Carbocisteine | Mucin composition/viscosity | Chronic productive COPD; selected bronchiectasis | GI ulcer/bleeding risk and response must be reviewed |
| Dornase alfa | Extracellular DNA | Cystic fibrosis | Specialist, costly, indication-specific enzyme therapy |
| Hypertonic saline | Airway-surface hydration | CF/bronchiectasis airway-clearance programmes | Bronchospasm, cough and need for supervised protocol |
When mucolytics should not be used routinely
- Acute viral upper-respiratory infection or uncomplicated acute bronchitis: routine mucolytics are not recommended.
- Dry cough without retained sputum: thinning mucus may not provide benefit.
- Unassessed severe breathlessness or suspected airway obstruction: resuscitate and diagnose first.
- Patients unable to cough, swallow or protect the airway: arrange suction and airway support rather than relying on oral mucolysis.
- Suspected pulmonary haemorrhage, aspiration, foreign body or pneumothorax: urgent evaluation takes priority.
Emergency airway-clearance approach
- Assess ABCDE: oxygenation, ventilation, consciousness, respiratory effort and haemodynamics.
- Position and oxygenate: sit upright where appropriate, give controlled oxygen to the target range and monitor continuously in severe illness.
- Open the airway: suction the mouth and airway when secretions are obstructing; consider an advanced airway if protective reflexes fail.
- Treat bronchospasm: give prescribed bronchodilator therapy if wheeze/bronchospasm is present, remembering that mucolytic-induced bronchospasm can occur.
- Mobilise secretions: humidification, physiotherapy, assisted cough, positive expiratory pressure or nebulised therapy may help selected patients.
- Escalate: persistent lobar collapse, mucus plugging, worsening gas exchange or inability to clear secretions may require bronchoscopy, non-invasive ventilation or intubation.
Interactions, contraindications and monitoring
- Antitussives: avoid suppressing an effective productive cough while aggressively thinning secretions unless there is a specific reason and airway clearance is assured.
- Bronchodilators: acetylcysteine or hypertonic saline may provoke bronchospasm; bronchodilator pre-treatment can be appropriate for susceptible patients.
- Peptic ulcer disease: carbocisteine and bromhexine/ambroxol require caution; investigate GI bleeding or severe pain.
- Renal/hepatic impairment: oral doses and product choice may require review; do not assume a mucolytic is risk-free because it is not a bronchodilator.
- Monitoring: sputum viscosity and volume, cough effectiveness, oxygen saturation, wheeze, respiratory rate, lung function where available, hydration, GI symptoms and clinical response.
- Stop criteria: no benefit, recurrent bronchospasm, severe rash/mucosal lesions, GI bleeding, worsening breathlessness or inability to manage increased secretions.
Clinical cases
Case 1: COPD with chronic thick sputum
Confirm that the patient has chronic productive cough and difficulty expectorating rather than a new pneumonia or heart-failure presentation. Review inhalers, smoking, hydration, airway-clearance technique and exacerbation history. A monitored trial of carbocisteine or another locally recommended mucolytic may be reasonable; stop if there is no meaningful improvement.
Case 2: asthma patient develops wheeze during nebulised acetylcysteine
Stop the mucolytic, assess airway and oxygenation, and treat bronchospasm with appropriate bronchodilator therapy. The episode does not mean the patient needs a higher mucolytic dose. In future, consider specialist pre-treatment or an alternative airway-clearance plan.
Case 3: cystic fibrosis with very tenacious sputum
Dornase alfa may be used according to the CF team’s protocol, commonly 2.5 mg nebulised daily, with airway-clearance physiotherapy. Do not mix it in the same nebuliser with other drugs. Monitor pulmonary function, sputum clearance, infection and treatment adherence.
High-yield revision points
- Mucolytics reduce mucus viscosity; they do not treat the cause of every cough.
- Acetylcysteine splits disulfide bonds and may provoke bronchospasm or bronchorrhoea.
- Bromhexine and ambroxol are related mucokinetic/secretolytic agents; product doses vary.
- Carbocisteine is an oral mucoregulator used selectively in chronic productive COPD and similar disorders.
- Dornase alfa cleaves extracellular DNA and is primarily a cystic-fibrosis therapy.
- Hypertonic saline hydrates airway secretions but requires a supervised airway-clearance plan.
- Do not use antitussives indiscriminately when a patient needs to cough up retained sputum.
- Airway suction, physiotherapy, bronchoscopy and ventilatory support may be more urgent than any mucolytic.
